The therapeutic area of anti-infectives has a very large patient base in China. We have two flagship originator branded anti-bacterial drugs,Vancocin® and Ceclor®.

Our Ceclor® manufacturing facility is equipped with state-of-the-art equipment, modules and production lines throughout our manufacturing processes, which were imported from globally leading companies from Sweden, Germany and Italy.

The therapeutic area of anti-infectives has a very large patient base in China. We have two flagship originator branded anti-bacterial drugs,Vancocin® and Ceclor®.

Our Ceclor® manufacturing facility is equipped with state-of-the-art equipment, modules and production lines throughout our manufacturing processes, which were imported from globally leading companies from Sweden, Germany and Italy.

CVD was China’s third largest therapeutic area in 2022,and there were approximately 330 million CVD patients in China.Statin therapy may reduce the risk of major CV events by approximately only 25% to 35% primarily through lowering LDL-C levels, leaving significant persistent CV risk of approximately 65% to 75%.

Icosapent ethyl (“IPE”) is the first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in targeted high-risk patients, according to the Frost & Sullivan Report. Vascepa® received its new drug approval from the FDA in 2012 and was launched in the U.S. in 2013, initially for use as an adjunct to diet to reduce TG.Moreover, Vascepa® was approved by the FDA for a cardiovascular risk reduction (“CRR”) indication in 2019 as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated TG levels (≥150mg/dL). We in-licensed Vascepa® from Amarin in 2015 for development and commercialization.

CVD was China’s third largest therapeutic area in 2022,and there were approximately 330 million CVD patients in China.Statin therapy may reduce the risk of major CV events by approximately only 25% to 35% primarily through lowering LDL-C levels, leaving significant persistent CV risk of approximately 65% to 75%.

Icosapent ethyl (“IPE”) is the first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in targeted high-risk patients, according to the Frost & Sullivan Report. Vascepa® received its new drug approval from the FDA in 2012 and was launched in the U.S. in 2013, initially for use as an adjunct to diet to reduce TG.Moreover, Vascepa® was approved by the FDA for a cardiovascular risk reduction (“CRR”) indication in 2019 as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated TG levels (≥150mg/dL). We in-licensed Vascepa® from Amarin in 2015 for development and commercialization.

Respiratory system is one of the fastest-growing and emerging therapeutic areas in China. Both asthma and COPD have strong prevalence in China and have been significantly underdiagnosed and undertreated.The Health China 2030 plan set a target to significantly increase diagnosis rate of COPD and lower the mortality rate of COPD.


ICSs are by far the most effective controller used in the treatment of asthma and one of a few types of drugs that can effectively suppress the characteristic inflammation in asthmatic airways. FPN is the latest-generation ICS nebulizer indicated for the treatment of asthma. Also, we are developing generic versions of two ICS/LABA combination DPI drug, ERC 301 and ERC 302 for treatment of asthma and COPD.


Our respiratory R&D Center in Suzhou, with the robust and proprietary quality management system, is dedicated to ensuring high quality standards of the respiratory products in the future.

Respiratory system is one of the fastest-growing and emerging therapeutic areas in China. Both asthma and COPD have strong prevalence in China and have been significantly underdiagnosed and undertreated.The Health China 2030 plan set a target to significantly increase diagnosis rate of COPD and lower the mortality rate of COPD.


ICSs are by far the most effective controller used in the treatment of asthma and one of a few types of drugs that can effectively suppress the characteristic inflammation in asthmatic airways. FPN is the latest-generation ICS nebulizer indicated for the treatment of asthma. Also, we are developing generic versions of two ICS/LABA combination DPI drug, ERC 301 and ERC 302 for treatment of asthma and COPD.


Our respiratory R&D Center in Suzhou, with the robust and proprietary quality management system, is dedicated to ensuring high quality standards of the respiratory products in the future.

There are other branded drugs operating on our platform, covering the area of hematology, nervous system diseases and many other fields,creating a diversified product portfolio to provide more options for Chinese patients.

There are other branded drugs operating on our platform, covering the area of hematology, nervous system diseases and many other fields,creating a diversified product portfolio to provide more options for Chinese patients.

Unit 122-129, Building A3, No. 700, Wanrong Road, Shanghai,China

pr@eddingpharm.com

沪ICP备2021007464号

Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038